FAPI PET/CT与FDG PET/CT预测附件肿瘤恶性潜能:一例卵巢交界性肿瘤病例报告
54岁女性附件区55×64mm肿瘤,[18F]FDG PET/CT示高摄取提示卵巢癌可能,术前[68Ga]-Ga-FAPI-46 PET/CT示低摄取,病理证实为交界性卵巢肿瘤。本例提示[68Ga]-Ga-FAPI-46 PET/CT在鉴别恶性附件肿瘤与交界性卵巢肿瘤方面可能优于[18F]-FDG PET/CT。
要点
- 54岁女性附件区55×64mm肿瘤,[18F]FDG PET/CT示高摄取,高度提示卵巢癌。
- 术前[68Ga]-Ga-FAPI-46 PET/CT示肿瘤低摄取,病理证实为交界性卵巢肿瘤。
- 作者认为[68Ga]-Ga-FAPI-46 PET/CT在鉴别恶性附件肿瘤与交界性卵巢肿瘤方面可能优于[18F]-FDG PET/CT。
核心结论
- 本例提示[68Ga]-Ga-FAPI-46 PET/CT在鉴别恶性附件肿瘤与交界性卵巢肿瘤方面可能优于[18F]-FDG PET/CT。
研究设计与样本
- 病例报告:54岁女性,附件区55×64mm肿瘤,术前接受[18F]FDG PET/CT和[68Ga]-Ga-FAPI-46 PET/CT检查,术后行组织病理学检查。
主要发现
- 术前[18F]FDG PET/CT示肿瘤高[18F]FDG摄取,高度提示卵巢癌。
- 术前[68Ga]-Ga-FAPI-46 PET/CT示肿瘤低[68Ga]-Ga-FAPI-46摄取。
- 组织病理学显示为交界性卵巢肿瘤,恶性潜能低,10年生存率大于93%。
关键数值与推荐
- 高[18F]FDG摄取被认为是附件肿瘤恶性的较好预测指标。
- 交界性卵巢肿瘤恶性潜能低,10年生存率大于93%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 54-year-old woman presented with a 55 × 64-mm tumor in the ovary with high [ 18 F]FDG uptake on [ 18 F]FDG PET/CT highly suggestive of ovarian cancer. Prior to surgery, the patient underwent [ 68 Ga]-Ga- fibroblast activation protein inhibitor (FAPI)-46 PET/CT, which revealed low [ 68 Ga]-Ga-FAPI-46 tumor uptake. Histopathology revealed a borderline ovarian tumor, which has low malignant potential and a 10-year survival rate greater than 93%. High [ 18 F]FDG uptake is considered a fair predictor of malignancy in adnexal tumors. The present case demonstrates the potential superiority of [ 68 Ga]-Ga-FAPI-46 PET/CT over [ 18 F]-FDG PET/CT in differentiating malignant adnexal tumors from borderline ovarian tumors.
引用
- Umachanger JK, Zacho HD, Sylvest C, et al. Predicting Malignancy in Adnexal Tumors With FAPI PET/CT and FDG PET/CT: A Case Report on a Borderline Ovarian Tumor. Clin Nucl Med. 2024. PMID: 39479983. doi:10.1097/RLU.0000000000005537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。